Influence of PVP molecular weight on the microwave assisted in situ amorphization of indomethacin

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Influence of PVP molecular weight on the microwave assisted in situ amorphization of indomethacin. / Doreth, Maria; Löbmann, Korbinian; Priemel, Petra; Grohganz, Holger; Taylor, Robert; Holm, René; Lopez de Diego, Heidi; Rades, Thomas.

In: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Vol. 122, 01.2018, p. 62-69.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Doreth, M, Löbmann, K, Priemel, P, Grohganz, H, Taylor, R, Holm, R, Lopez de Diego, H & Rades, T 2018, 'Influence of PVP molecular weight on the microwave assisted in situ amorphization of indomethacin', European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, vol. 122, pp. 62-69. https://doi.org/10.1016/j.ejpb.2017.10.001

APA

Doreth, M., Löbmann, K., Priemel, P., Grohganz, H., Taylor, R., Holm, R., Lopez de Diego, H., & Rades, T. (2018). Influence of PVP molecular weight on the microwave assisted in situ amorphization of indomethacin. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 122, 62-69. https://doi.org/10.1016/j.ejpb.2017.10.001

Vancouver

Doreth M, Löbmann K, Priemel P, Grohganz H, Taylor R, Holm R et al. Influence of PVP molecular weight on the microwave assisted in situ amorphization of indomethacin. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 2018 Jan;122:62-69. https://doi.org/10.1016/j.ejpb.2017.10.001

Author

Doreth, Maria ; Löbmann, Korbinian ; Priemel, Petra ; Grohganz, Holger ; Taylor, Robert ; Holm, René ; Lopez de Diego, Heidi ; Rades, Thomas. / Influence of PVP molecular weight on the microwave assisted in situ amorphization of indomethacin. In: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 2018 ; Vol. 122. pp. 62-69.

Bibtex

@article{17d0d27f0908465bbc7288fdb7aeb611,
title = "Influence of PVP molecular weight on the microwave assisted in situ amorphization of indomethacin",
abstract = "In situ amorphization is an approach that enables a phase transition of a crystalline drug to its amorphous form immediately prior to administration. In this study, three different polyvinylpyrrolidones (PVP K12, K17 and K25) were selected to investigate the influence of the molecular weight of the polymer on the degree of amorphization of the model drug indomethacin (IND) upon microwaving. Powder mixtures of crystalline IND and the respective PVP were compacted at 1:2 (w/w) IND:PVP ratios, stored at 54% RH and subsequently microwaved with a total energy input of 90 or 180 kJ. After storage, all compacts had a similar moisture content (∼10% (w/w)). Upon microwaving with an energy input of 180 kJ, 58 ± 4% of IND in IND:PVP K12 compacts was amorphized, whereas 31 ± 8% of IND was amorphized by an energy input of 90 kJ. The drug stayed fully crystalline in all IND:PVP K17 and IND:PVP K25 compacts. After plasticization by moisture, PVP K12 reached a Tg below ambient temperature (16 ± 2 °C) indicating that the Tg of the plasticized polymer is a key factor for the success of in situ amorphization. DSC analysis showed that the amorphized drug was part of a ternary glass solution consisting of IND, PVP K12 and water. In dissolution tests, IND:PVP K12 compacts showed a delayed initial drug release due to a lack of compact disintegration, but reached a higher total drug release eventually. In summary, this study showed that the microwave assisted in situ amorphization was highly dependent on the Tg of the plasticized polymer.",
keywords = "Journal Article",
author = "Maria Doreth and Korbinian L{\"o}bmann and Petra Priemel and Holger Grohganz and Robert Taylor and Ren{\'e} Holm and {Lopez de Diego}, Heidi and Thomas Rades",
note = "Copyright {\textcopyright} 2017. Published by Elsevier B.V.",
year = "2018",
month = jan,
doi = "10.1016/j.ejpb.2017.10.001",
language = "English",
volume = "122",
pages = "62--69",
journal = "European Journal of Pharmaceutics and Biopharmaceutics",
issn = "0939-6411",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Influence of PVP molecular weight on the microwave assisted in situ amorphization of indomethacin

AU - Doreth, Maria

AU - Löbmann, Korbinian

AU - Priemel, Petra

AU - Grohganz, Holger

AU - Taylor, Robert

AU - Holm, René

AU - Lopez de Diego, Heidi

AU - Rades, Thomas

N1 - Copyright © 2017. Published by Elsevier B.V.

PY - 2018/1

Y1 - 2018/1

N2 - In situ amorphization is an approach that enables a phase transition of a crystalline drug to its amorphous form immediately prior to administration. In this study, three different polyvinylpyrrolidones (PVP K12, K17 and K25) were selected to investigate the influence of the molecular weight of the polymer on the degree of amorphization of the model drug indomethacin (IND) upon microwaving. Powder mixtures of crystalline IND and the respective PVP were compacted at 1:2 (w/w) IND:PVP ratios, stored at 54% RH and subsequently microwaved with a total energy input of 90 or 180 kJ. After storage, all compacts had a similar moisture content (∼10% (w/w)). Upon microwaving with an energy input of 180 kJ, 58 ± 4% of IND in IND:PVP K12 compacts was amorphized, whereas 31 ± 8% of IND was amorphized by an energy input of 90 kJ. The drug stayed fully crystalline in all IND:PVP K17 and IND:PVP K25 compacts. After plasticization by moisture, PVP K12 reached a Tg below ambient temperature (16 ± 2 °C) indicating that the Tg of the plasticized polymer is a key factor for the success of in situ amorphization. DSC analysis showed that the amorphized drug was part of a ternary glass solution consisting of IND, PVP K12 and water. In dissolution tests, IND:PVP K12 compacts showed a delayed initial drug release due to a lack of compact disintegration, but reached a higher total drug release eventually. In summary, this study showed that the microwave assisted in situ amorphization was highly dependent on the Tg of the plasticized polymer.

AB - In situ amorphization is an approach that enables a phase transition of a crystalline drug to its amorphous form immediately prior to administration. In this study, three different polyvinylpyrrolidones (PVP K12, K17 and K25) were selected to investigate the influence of the molecular weight of the polymer on the degree of amorphization of the model drug indomethacin (IND) upon microwaving. Powder mixtures of crystalline IND and the respective PVP were compacted at 1:2 (w/w) IND:PVP ratios, stored at 54% RH and subsequently microwaved with a total energy input of 90 or 180 kJ. After storage, all compacts had a similar moisture content (∼10% (w/w)). Upon microwaving with an energy input of 180 kJ, 58 ± 4% of IND in IND:PVP K12 compacts was amorphized, whereas 31 ± 8% of IND was amorphized by an energy input of 90 kJ. The drug stayed fully crystalline in all IND:PVP K17 and IND:PVP K25 compacts. After plasticization by moisture, PVP K12 reached a Tg below ambient temperature (16 ± 2 °C) indicating that the Tg of the plasticized polymer is a key factor for the success of in situ amorphization. DSC analysis showed that the amorphized drug was part of a ternary glass solution consisting of IND, PVP K12 and water. In dissolution tests, IND:PVP K12 compacts showed a delayed initial drug release due to a lack of compact disintegration, but reached a higher total drug release eventually. In summary, this study showed that the microwave assisted in situ amorphization was highly dependent on the Tg of the plasticized polymer.

KW - Journal Article

U2 - 10.1016/j.ejpb.2017.10.001

DO - 10.1016/j.ejpb.2017.10.001

M3 - Journal article

C2 - 28986296

VL - 122

SP - 62

EP - 69

JO - European Journal of Pharmaceutics and Biopharmaceutics

JF - European Journal of Pharmaceutics and Biopharmaceutics

SN - 0939-6411

ER -

ID: 185403119